Belluscura PLC Result of General Meeting
27 August 2024 - 11:17PM
RNS Regulatory News
RNS Number : 8597B
Belluscura PLC
27 August 2024
27 August 2024
Belluscura plc
("Belluscura" or the
"Company")
Result of General
Meeting
Belluscura plc (AIM: BELL), a
leading medical device developer focused on lightweight and
portable oxygen enrichment technology, announces that at the Annual General Meeting held earlier
today, all resolutions proposed were duly approved by
shareholders:
|
|
Total votes
for
|
% of shares
voted
|
Total votes
against
|
% of shares
voted
|
Total votes
|
Votes
withheld
|
|
Ordinary resolutions
|
|
|
|
|
|
|
|
Resolution 1: To receive and adopt
the report of the directors and the audited accounts of the Company
for the period ended 31 December 2023
|
91,444,802
|
99.94
|
55,722
|
0.06
|
91,500,524
|
-
|
|
Resolution 2: To re-elect Simon
Neicheril as a director of the Company
|
91,426,718
|
99.94
|
54,753
|
0.06
|
91,481,471
|
19,053
|
|
Resolution 3: To re-elect Robert
Fary as a director of the Company
|
91,426,718
|
99.94
|
54,753
|
0.06
|
91,481,471
|
19,053
|
|
Resolution 4: To re-elect Paul Tuson
as a director of the Company
|
91,426,574
|
99.94
|
54,897
|
0.06
|
91,481,471
|
19,053
|
|
Resolution 5: To re-appoint Gerald
Edelman LLP as auditor to the Company
|
91,456,503
|
99.95
|
43,877
|
0.05
|
91,500,380
|
144
|
|
Resolution 6: To authorise the
directors to determine the remuneration of the auditors
|
91,442,594
|
99.96
|
38,877
|
0.04
|
91,481,471
|
19,053
|
|
Resolution 7: To grant the directors
authority to allot shares pursuant to Section 551 of the Companies
Act 2006 and grant rights to subscribe for, or convert any security
into, shares
|
91,439,344
|
99.93
|
61,180
|
0.07
|
91,500,524
|
-
|
|
Special resolutions
|
|
|
|
|
|
|
|
Resolution 8: To dis-apply
pre-emption rights pursuant to Section 570 of the Companies Act
2006
|
86,818,255
|
94.90
|
4,663,216
|
5.10
|
91,481,471
|
19,053
|
|
Resolution 9: To authorise the
directors to make market purchases
|
86,896,258
|
94.97
|
4,604,266
|
5.03
|
91,500,524
|
-
|
For
further information please contact:
|
Belluscura
plc
|
Tel: +44 (0)20 3128
8100
|
|
Adam Reynolds, Chairman
Robert Rauker, Chief Executive
Officer
Simon Neicheril, Chief Financial
Officer
|
|
|
|
|
|
SPARK Advisory
Partners Limited
(Nominated
Adviser)
|
Tel: +44 (0)20 3368
3550
|
|
Neil Baldwin / Jade Bayat
|
|
|
|
|
|
Dowgate
Capital Limited
(Broker)
|
Tel: +44 (0)20 3903
7715
|
|
James Serjeant / Russell Cook
|
|
|
|
|
|
MHP Group
(Financial PR
& Investor Relations)
|
Tel: +44 (0)20 3128
8100
|
|
Katie Hunt / Matthew
Taylor
|
belluscura@mhpgroup.com
|
About Belluscura plc (https://belluscura.com/)
Belluscura is a UK medical device
company focused on developing oxygen enrichment technology spanning
broad industries and therapies. Our innovative oxygen technologies
are designed with a global purpose: to create improved health and
economic outcomes for the patients, healthcare providers and
insurance organisations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
AGMEADPXAFKLEFA
Belluscura (LSE:BELL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Belluscura (LSE:BELL)
Historical Stock Chart
From Dec 2023 to Dec 2024
